A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Reishi Mushroom ( Ganoderma lucidum ), Stinging Nettle ( Urtica dioica ), and Epimedium ( Epimedium sagittatum )
Jarred Younger,
Emily K. Donovan,
Kathleen S. Hodgin and
Timothy J. Ness
Additional contact information
Jarred Younger: Department of Psychology, University of Alabama at Birmingham, CH 233, 1300 University Boulevard, Birmingham, AL 35233, USA
Emily K. Donovan: Department of Psychology, Virginia Commonwealth University, White House, 806 West Franklin Street, Richmond, VA 23284, USA
Kathleen S. Hodgin: Department of Psychology, University of Alabama at Birmingham, CH 233, 1300 University Boulevard, Birmingham, AL 35233, USA
Timothy J. Ness: Department of Anesthesiology and Perioperative Medicine, University of Alabama at Birmingham, BMR2-208, 901 19th Street South, Birmingham, AL 35205, USA
IJERPH, 2021, vol. 18, issue 7, 1-13
Abstract:
This report is third in a three-part clinical trial series screening potential treatments for Gulf War Illness (GWI). The goal of the project was to rapidly identify agents to prioritize for further efficacy research. We used a placebo-controlled, pseudo-randomized, crossover design to test the effects of reishi mushroom ( Ganoderma lucidum ), stinging nettle ( Uritca dioica ), and epimedium ( Epimedium sagittatum ) in 29 men with GWI. Participants completed 30 days of symptom reports for baseline, then a botanical line consisting of 30 days of placebo, followed by 30 days each of lower-dose and higher-dose botanical. After completing a botanical line, participants were randomized to complete the protocol with another botanical, until they completed three botanical trials. GWI symptom severity, pain, and fatigue were contrasted between the four conditions (baseline, placebo, lower-dose, higher dose) using linear mixed models. GWI symptom severity was unchanged from placebo in the reishi lower-dose condition ( p = 0.603), and was higher in the higher-dose condition ( p = 0.012). Symptom severity was not decreased from placebo with lower-dose stinging nettle ( p = 0.604), but was significantly decreased with higher-dose stinging nettle ( p = 0.048). Epimedium showed no significant decreases of GWI symptoms in the lower ( p = 0.936) or higher ( p = 0.183) dose conditions. Stinging nettle, especially at higher daily dosages, may help reduce the symptoms of GWI. Epimedium does not appear to beneficially affect GWI symptom severity, and reishi may exaggerate symptoms in some GWI sufferers. These results are in a small sample and are preliminary. Further research is required to determine if stinging nettle is indeed helpful for the treatment of GWI, and what dosage is optimal. This trial was registered on ClinicalTrials.gov (NCT02909686).
Keywords: reishi; stinging nettle; epimedium (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:
Downloads: (external link)
https://www.mdpi.com/1660-4601/18/7/3671/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/7/3671/ (text/html)
Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
HTML/Text
Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:7:p:3671-:d:528244
Access Statistics for this article
IJERPH is currently edited by Ms. Jenna Liu
More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().